• Zimmer Biomet’s recently reported second-quarter results highlighted ongoing strength in its hip triple-play and knee portfolios, even as analysts reassessed the company’s muted revenue growth and modest 4.2% return on capital in light of its long operating history and global scale.
• The key tension now is between solid procedural demand in core orthopedics and growing concern that management has limited avenues for highly profitable expansion.
• Next, we’ll explore how this mix of resilient hip and knee demand and concerns about muted growth shapes Zimmer Biomet’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Zimmer Biomet Holdings Investment Narrative Recap

To own Zimmer Biomet, you need to believe that steady global demand for hip and knee procedures can offset relatively muted revenue growth and modest returns on capital. The latest second quarter update, which reaffirmed solid hip triple-play and knee momentum, does little to change the near term picture: the key catalyst remains dependable procedure volumes, while the biggest risk is that limited high margin growth avenues keep long term profitability constrained.

Among recent announcements, Zimmer Biomet’s refreshed 2026 revenue guidance range of 2.5% to 4.5% stands out as most relevant, because it frames expectations for how far today’s hip and knee strength can carry overall growth. With revenue still forecast to trail the wider US market, investors watching this guidance against emerging pricing pressures and reimbursement headwinds will be better positioned to judge whether today’s stable demand can meaningfully improve margins and returns.

Yet beneath resilient procedure trends, investors should still pay close attention to the risk that flat selling prices and reimbursement pressures could...

Zimmer Biomet Holdings' narrative projects $9.2 billion revenue and $1.2 billion earnings by 2029. This requires 3.2% yearly revenue growth and roughly a $438.8 million earnings increase from $761.2 million today.

Uncover how Zimmer Biomet Holdings' forecasts yield a $98.70 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently see Zimmer Biomet’s fair value between US$98.70 and US$230.01, highlighting very different expectations. Set against concerns about muted revenue growth and pricing pressure, this spread underlines why it can pay to review several independent views before deciding how Zimmer Biomet might fit into your portfolio.

Explore 4 other fair value estimates on Zimmer Biomet Holdings - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Zimmer Biomet Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zimmer Biomet Holdings' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.